Marinomed Biotech AG Stock price

Equities

MARI

ATMARINOMED6

Pharmaceuticals

Delayed Wiener Boerse 12:35:13 2024-03-28 pm EDT 5-day change 1st Jan Change
21.9 EUR +4.29% Intraday chart for Marinomed Biotech AG +9.50% -25.00%
Sales 2023 * 13.5M 14.56M Sales 2024 * 18.5M 19.95M Capitalization 33.62M 36.27M
Net income 2023 * -5M -5.39M Net income 2024 * - 0 EV / Sales 2023 * 3.68 x
Net Debt 2023 * 16.05M 17.31M Net Debt 2024 * 17.11M 18.46M EV / Sales 2024 * 2.74 x
P/E ratio 2023 *
-6.54 x
P/E ratio 2024 *
-36.8 x
Employees 43
Yield 2023 *
-
Yield 2024 *
-
Free-Float 64.98%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.29%
1 week+9.50%
Current month-4.78%
1 month-3.52%
3 months-29.81%
6 months-45.66%
Current year-25.00%
More quotes
1 week
19.50
Extreme 19.5
22.00
1 month
19.50
Extreme 19.5
23.10
Current year
19.50
Extreme 19.5
32.00
1 year
19.50
Extreme 19.5
46.20
3 years
19.50
Extreme 19.5
141.00
5 years
19.50
Extreme 19.5
147.00
10 years
19.50
Extreme 19.5
147.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 05-12-31
Founder 56 05-12-31
Director of Finance/CFO 52 18-07-31
Members of the board TitleAgeSince
Chairman 58 07-12-31
Director/Board Member 68 18-11-20
Director/Board Member - 22-06-14
More insiders
Date Price Change Volume
24-03-28 21.9 +4.29% 7,678
24-03-27 21 +0.96% 2,141
24-03-26 20.8 +5.58% 597
24-03-25 19.7 -0.76% 88
24-03-22 19.85 -0.75% 336

Delayed Quote Wiener Boerse, March 28, 2024 at 12:35 pm EDT

More quotes
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
21.9 EUR
Average target price
66.53 EUR
Spread / Average Target
+203.79%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Marinomed Biotech AG - Wiener Boerse